SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Multi-omics identifies microbiota-derived deoxycholic acid as a key mediator of blood-brain barrier dysfunction in Parkinson's disease.

Imeta · 2025-09-17

DOI: 10.1002/imt2.70076PMID: 41112044

Open accessLetterOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

The gut microbiota derived from Parkinson's disease patients, enriched in Bacteroides fragilis (B. fragilis) and Phocaeicola vulgatus (P. vulgatus), may promote the elevations of deoxycholic acid, iso-deoxycholic acid, and ursodeoxycholic acid levels in the systemic circulation. The increased serum bile acids, in turn, contribute to the endothelial cell death and pericyte injury possibly through activating interferon alpha response and TGF-β signaling pathways at the blood-brain barrier in the midbrain, ultimately leading to the neurodegeneration and motor deficits in the germ-free mice.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.